Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Operating Expenses (2016 - 2025)

Amicus Therapeutics' Operating Expenses history spans 16 years, with the latest figure at $142.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 20.03% year-over-year to $142.7 million, compared with a TTM value of $528.5 million through Dec 2025, up 17.32%, and an annual FY2025 reading of $528.5 million, up 17.32% over the prior year.
  • Operating Expenses for Q4 2025 was $142.7 million at Amicus Therapeutics, up from $115.3 million in the prior quarter.
  • The five-year high for Operating Expenses was $148.9 million in Q2 2025, with the low at $100.4 million in Q2 2024.
  • Average Operating Expenses over 5 years is $119.9 million, with a median of $116.1 million recorded in 2023.
  • Year-over-year, Operating Expenses dropped 21.7% in 2023 and then soared 48.29% in 2025.
  • Tracing FOLD's Operating Expenses over 5 years: stood at $146.4 million in 2021, then dropped by 17.35% to $121.0 million in 2022, then fell by 11.23% to $107.4 million in 2023, then rose by 10.66% to $118.9 million in 2024, then increased by 20.03% to $142.7 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Operating Expenses are $142.7 million (Q4 2025), $115.3 million (Q3 2025), and $148.9 million (Q2 2025).